Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check3 days agoChange DetectedThe 403 error block and Home navigation were removed, allowing the study details page (NCT02834975) to be accessed and viewed as designed.SummaryDifference0.5%

- Check10 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating restricted access, and the study content is replaced by an error message while the site chrome remains visible.SummaryDifference19%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s revision tag was updated from v3.6.5 to v3.6.6, indicating a minor, backend update. There is no indication that the trial details or visible content were changed.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, reflecting an update to the page's underlying system version. This is a maintenance change and does not modify study details, eligibility criteria, or results.SummaryDifference0.1%

- Check66 days agoChange DetectedThe revision label on the page was updated to v3.6.4, signaling a small patch or update to the documented content.SummaryDifference0.1%

- Check88 days agoChange DetectedPage revision updated to v3.6.3, indicating a small update to the page's underlying template/assets; no study content changes are reflected in this update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.